首页> 外文期刊>Egyptian Journal of Medical Human Genetics >The role of glutathione S-transferase omega gene polymorphisms in childhood acute lymphoblastic leukemia: a case-control study
【24h】

The role of glutathione S-transferase omega gene polymorphisms in childhood acute lymphoblastic leukemia: a case-control study

机译:谷胱甘肽S转移酶Omega基因多态性在儿童急性淋巴细胞白血病中的作用:一种案例对照研究

获取原文
       

摘要

Background:Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Glutathione-S-methyl transferase (GSTs) enzymes’ family is known to catalyze carcinogens detoxification. Overexpression of (GSTO) omega class was reported in cancer occurrence. The purpose of the study was to investigate the association of GSTO1*A140D (rs4925) and GSTO2*N142D (rs156697) polymorphisms with the susceptibility to childhood ALL and to evaluate their prognostic impact. Genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism technique in 96 Egyptian pediatric?ALL patients and 99 controls.ResultsNo statistically significant different GSTO1*A140D genotype and allele distribution was observed among ALL cases and controls; however, a statistically significant different GSTO1*A140D genotype distribution was found between de novo ALL cases and controls [CC (37% vs. 56.6%), CA (47.8% vs. 40.4%), and AA (15.2% vs. 3.0%), respectively] (0.008). GSTO1*A140D variant genotypes’ frequency was significantly higher in de novo cases than in controls (63% vs. 43.4%) (0.028). The minor allele frequency (MAF) of GSTO1*A140D-A was significantly higher in de novo cases compared to controls (0.39 vs. 0.23) (0.005). Genotyping of GSTO2*N142D revealed a statistically significant difference of genotype distribution between ALL patients and controls [AA (26% vs. 36.3%), AG (62.5% vs. 61.6%), and GG (11.4% vs. 2.0%), respectively] (0.017) and between de novo ALL cases and controls [AA (37% vs. 36.3%), AG (45.7% vs. 61.6%), and GG (17.3% vs. 2.0%), respectively] (0.002). The MAF of GSTO2*N142D-G was significantly higher in ALL patients than in controls (0.42 vs. 0.32) (0.046). The high-risk ALL group had a higher frequency of GSTO1*A140D and GSTO2*N142D variant genotypes compared to corresponding wild genotypes and a higher frequency of combined polymorphisms compared to single polymorphisms and wild genotypes but with no statistically significant difference.ConclusionA statistically significant difference of GSTO1*A140D and GSTO2*N142D genotype distribution was detected between de novo ALL cases and controls. Compared to the control group, the MAF of GSTO1*A140D-A was overexpressed in de novo ALL cases and that of GSTO2*N142D-G was significantly higher in ALL patients. These findings suggest that the studied polymorphisms might play a significant role in the susceptibility to de novo childhood ALL in Egypt; however, GSTO1*A140D and/or GSTO2*N142D polymorphisms have no impact on ALL prognosis.
机译:背景:急性淋巴细胞白血病(全部)是最常见的儿童癌症。已知谷胱甘肽-S-甲基转移酶( GSTS )酶的家族催化致癌物质排毒。在癌症发生中报告了( gsto )omega类的过表达。该研究的目的是研究 GSTO1 * A140D(RS4925)和 GSTO2 * N142D(RS156697)多态性的关键态随着童年的易感性并评估其预后影响。在96埃及儿科的聚合酶链反应限制片段长度多态性技术进行基因分型?所有患者和99次对照。统计学上显着的不同 GSTO1 * A140D 在所有病例和对照中观察到基因型和等位基因分布;然而,在De Novo所有病例和对照之间发现了统计学上显着的不同 GSTO1 * A140D 基因型分布[CC(37%对56.6%),CA(47.8%vs.40.4%)和AA (15.2%vs.3.0%),分别为(0.008)。 GSTO1 * A140D 变体基因型在Novo病例中的频率显着高于对照(63%vs.3.4%)(0.028)。与对照(0.39对0.23)(0.005)相比,De Novo病例中的次要等位基因频率(MAF)的次数频率(MAF)显着高于Novo病例(0.23)(0.005)。 GSTO2 * N142D的基因分型在所有患者和对照之间揭示了基因型分布的统计学意义差异[AA(26%对36.3%),Ag(62.5%vs.61.6%)和GG(11.4 %vs.2.0%)(0.017)和De Novo所有病例和对照组(37%对36.3%),Ag(45.7%与61.6%)和GG(17.3%Vs. 2.0%) )分别](0.002)。所有患者的MAF的 GSTO2 * N142D-G 比对照(0.42 vs.0.32)(0.046)。与相应的野生基因型相比,高风险所有组均具有较高的 GSTO1 * A140D 和 GSTO2 * N142D 变体基因型。与单一多态性相比,与相应的野生基因型和更高的组合多态性较高的多态性相比和野生基因型,但没有统计学上显着的差异。结论统计上显着的差异 Gsto1 * A140D和 Gsto2 * N142D 基因型分布在De Novo所有病例和对照之间检测到。与对照组相比,在De Novo中的所有病例中过表达了MAF的 GSTO1 * A140D-A 在所有患者中, GSTO2 * N142D-G / I>的含量显着高。这些研究结果表明,研究的多态性可能在埃及的易感性中发挥重要作用;然而, GSTO1 * A140D 和/或 GSTO2 * N142D 多态性对所有预后没有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号